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New Horizons article for Age and Ageing 
 
 “The area we would like you to focus on is new approaches to improving tolerability of chemotherapy in 
older people. Whilst a fair bit has been written on frailty assessment in patients with cancer ( which is an 
area geriatricians know a lot about) there has been much less exposure in the geriatric medicine literature 
on the topic of reducing toxicity and improving tolerability of therapies in older people. 
 Some key areas I would be keen for the article to address would be issues around patient selction, benefits 
of newer agents with improved toxicity profiles, dose adjustment with age or fragility and the role of highly 
targeted therapies.” 
 ~3000 words, 30-50 references. 
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Abstract 
 
Cancer is a disease associated with ageing. Increased life expectancy means that 
cancer in older adults is becoming an increasingly common problem. There are 
unique issues to consider when making decisions about cancer treatment in older 
populations.  Unfortunately, however, this group is still under-represented in clinical 
trials for new cancer therapies meaning there are less evidence based data to guide 
management. This articles aims to look at how we can optimise cancer treatment for 
elderly patients with a focus on Systemic Anti-Cancer Therapy (SACT) and 
addressing particular issues around patient selection, improving treatment tolerance 
and use of newer agents with different toxicity profiles. 
 
Keywords- cancer, elderly, chemotherapy, targeted therapy, 
immunotherapy, toxicity, trials, systemic anti-cancer therapy 
 
Key points 
 With an ageing population there will be an increasing number of older 
patients living with, and undergoing treatment for, cancer. 
 In recent years there has been a rapid expansion of the range of Systemic 
Anti-Cancer therapy (SACT) options available to the older population 
 There are particular issues associated with the use of SACT  in elderly 
patients 
 There should be an initial comprehensive assessment to address which 
patients should be offered SACT and allow optimisation of patients’ health 
prior to embarking upon it 
 There should be ongoing attention to and, as far as possible, minimisation of 
SACT toxicity throughout and after treatment. 
 Elderly patients are under –represented in clinical trials for SACT and we 
need to improve their recruitment levels. 
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Introduction 
With an ageing population and a continued increase in life expectancy, cancer in the 
older person has become an increasingly common problem in the Western world. 
More than three-quarters of cancer deaths occur in people aged 65 years and over, 
and more than half (52%) in those aged 75 years and over. (1) 
Whilst the cancer burden is highest in the older age group, there is a growing body of 
evidence to suggest older patients are less likely to receive the most clinically 
effective treatment for their cancer. (2) (3) (4) Suboptimal treatment can lead to less 
favourable cancer outcomes and impact negatively on cancer survival rates.  
Concerns have been raised that current methods of assessing older patients do not 
provide sufficient information to make appropriate cancer treatment 
recommendations. Poorly managed co-morbidtities, as well as lack of practical and 
social support ,can also prevent patients receiving optimum treatment for their 
cancer.(5) 
Cancer treatment can include surgery, radiotherapy and pharmacotherapy. This 
article focuses on specific issues related to the latter, reflecting on the use of 
Systemic Anti-Cancer Therapy (SACT) in older adults. It encompasses a summary of 
current SACTs available, including newer agents with different toxicity profiles, the 
existing evidence base and special considerations for the use of SACT in older 
people and provides suggestions of how cancer treatment might be improved for this 
population. 
Systemic Anti-Cancer Therapy (SACT) 
SACT encompasses a host of pharmacological therapies that can be used with 
curative intent either neoadjuvantly with an aim to reduce the size or extent of the 
cancer before using radical treatment intervention or adjuvantly when given after the 
primary treatment to lower the cancer recurrence risk. They can also be used 
palliatively to prolong life or reduce symptoms. 
SACT can be divided into four main categories: 
1) Chemotherapy which  encompasses traditional chemotoxic agents relying on the 
propensity of cells to die when their DNA is damaged by therapeutic means. 
Chemotherapies are not designed to specifically target malignant cells and therefore 
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many have a range of side effects that relate to their anti-proliferative actions such as 
alopecia, gastro-intestinal symptoms and myelosuppression.  In addition, 
chemotherapy agents may have their own unique class specific side effects (Table 
1). 
2) Hormonal (Endocrine) therapy which deprives malignant cells of growth and 
survival promoting hormones. It is used for cancers derived from hormonally 
responsive tissues including breast, prostate and endometrium. It may work by 
inhibiting the production of hormones in their place of origin, inducing a chemical 
castration, or binding to the hormone receptor and preventing its activation. Potential 
side effects include increased risk of osteoporosis, metabolic syndrome, mood 
disorders, sexual dysfunction and impaired quality of life. 
3) Newer targeted agents which work by interfering with specific molecules that are 
involved in the growth, progression and spread of cancer. They are frequently used 
in a sub-population who exhibit a specific molecular biomarker and may also be 
referred to as molecularly targeted therapies. They essentially target the underlying 
reason why the cells are multiplying out of control and are currently the focus of 
much anti-cancer drug development. Small molecule kinase inhibitors and 
monoclonal antibodies (mAbs) constitute the majority of these agents. Targets 
include; 
-extracellular growth factor receptors such as Human Epidermal Growth Factor 
Receptor 2 (HER2). Trastuzumab is a monoclonal antibody directed against the 
extracellular segment of the HER2 receptor. The HER2 pathway promotes cell 
growth and division when it is functioning normally but when overexpressed cell 
growth accelerates beyond normal limits which can lead to rapid cell proliferation and 
tumour formation. The HER2 gene is amplified in 20-30% of early stage breast 
cancers and in patients with this overexpression of HER2, Trastuzumab can bind to 
the extracellular segment of the HER2 receptor preventing the growth factor receptor 
from working properly and inducing immune cells to kill that cell through antibody 
dependent cell mediated cytotoxicity. 
- intracellular signal transduction pathways. Tyrosine kinases are enzymes that 
serve as intracellular messengers and help to send growth signals in the cell. 
Tyrosine Kinase Inhibitors (TKIs) are a class of agents that therefore interfere with 
signal transduction and can prevent cells growing and dividing. Erlotinib is a TKI that 
targets the epidermal growth factor receptor and has been shown to be effective in 
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the treatment of patients with metastatic non-small cell lung cancer. 
- angiogenesis. Vascular Endothelial Growth Factor is a signal protein that 
stimulates new blood vessel formation. Bevacizumab is a monoclonal antibody that 
inhibits vascular endothelial growth factor. A blood supply is necessary for tumours to 
grow beyond a certain size so treatments that interfere with angiogenesis may block 
tumour growth. 
4) Immunotherapies which can either stimulate the specific components of the 
immune system against the tumour cells or counteract signals produced by cancer 
cells that suppress immune responses.  For example the immune checkpoint 
inhibitor Ipilimumab, used for the treatment of metastatic melanoma, is a monoclonal 
antibody which blocks the activity of a checkpoint protein CTLA- 4 which is 
expressed on the surface of activated T- lymphocytes. CTLA-4 serves to inactivate 
the T- cells and dampen the immune response and Ipilimumab therefore acts to 
prevent this inhibitory signal. 
The expansion of newer targeted therapies and immunotherapies has been 
exponential in the last decade.  These drugs require new approaches to optimise 
dosing, to assess patient adherence and to evaluate treatment effectiveness. In 
general they are tolerated better than traditional chemotherapy but are associated 
with their own range of adverse effects (Table 2). A review of the existing literature 
on the effects of targeted therapies in older people, has suggested that their early 
promise in terms of providing better tolerability has not yet been realised.(6) 
 
 
Evidence for SACT in older people 
Despite the potential for more treatment complications, available data suggests that 
chemotherapy can be safe and effective in older patients (7) (8) (9). However, few 
studies to date have included patients at extremes of age, or with poor performance 
status and there are therefore less evidence-based data to guide the treatment of 
these patients (10) (11).  
Trials 
The Adjuvant Chemotherapy in elderly Women with breast cancer (ACheW) 
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study (12) was an observational study that examined the patterns of treatment, and 
reasons for not offering treatment, in women with early breast cancer aged 70 years 
and over.  Out of 803 patients referred to 24 multi-disciplinary cancer teams in 
England, only 116 (14%) were offered chemotherapy and 66 (8%) received it. Only 4 
of 307 women (1.3%) aged over 80 years were offered chemotherapy. The most 
common reason for not offering chemotherapy was that ‘other treatments were more 
appropriate’ or ‘benefits were too small”. Interestingly, co-morbidities and frailty were 
less commonly cited as reasons but there was evidence of inadequate assessment 
as in up to 1/3 of cases the recommendation for chemotherapy was made in the 
absence of critical information regarding performance status and HER-2 status. It 
was notable that patterns of treatment and reasons given for not offering 
chemotherapy showed considerable variation across hospital sites. This suggests 
that there is little consensus on the best management options for this older patient 
group.  
The UK National Cancer Research Network Adjuvant Chemotherapy in Older 
women (ACTION) study (13) set out to address this issue in a randomised trial of 
adjuvant chemotherapy vs no chemotherapy in women aged over 70 years with early 
breast cancer. Unfortunately this study failed to recruit during the pilot phase, 
predominantly because the eligible older women who were approached were 
reluctant to participate in the study. The main conclusion was that a study that 
involved randomising older women to receive chemotherapy vs observation may not 
be a viable design for this patient population.  
The MRC FOCUS-2 trial (Chemotherapy options in elderly and frail patients with 
metastatic colorectal cancer) (14) was a pivotal trial in selectively recruiting an elderly 
and frail population with advanced colorectal cancer who were previously untreated 
and considered unfit for full-dose chemotherapy. It showed that, even in this 
population, combination therapy with oxaliplatin and fluoropyrimidines was still 
preferable to single agent fluoropyrimidine. In FOCUS -2 the drug doses were started 
at 80% of standard doses, an adaptation commonly adopted outside trial practice. 
The moderate low rates of toxicity, along with low uptake of therapy escalation at six 
weeks seem to support this strategy. The 321GO and GO2 trials are now testing a 
similar approach in advanced gastric and oesophageal cancer.(15) 
The ELVIS study (Elderly Lung cancer Vinorelbine Italian Study) was a randomized 
phase III trial in which patients older than 70 years affected by advanced Non Small 
Cell Lung cancer were randomized to receive best supportive care alone or best 
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supportive care plus chemotherapy with vinorelbine. The main end-point of the study 
was Quality of life and vinorelbine-treated patients scored better than control patients 
on Quality of life functioning scales, and also reported fewer lung cancer-related 
symptoms but did report worse toxicity-related symptoms.(16) 
National SACT dataset 
The national collection of all systemic anti cancer treatment information in the NHS in 
England commenced in April 2012 and has allowed creation of a national SACT 
dataset.  Similar data are available in Scotland. These data which relate to all cancer 
patients can be linked to information about patient demographics, co-morbidities   
and performance status as well as information about planned treatments, treatment 
modifications and intent of treatment. Analysis of these data also offers the potential 
to gain insight in to use of SACT amongst elderly patients. 
Designing trials 
The FOCUS- 2 and GO2 trials represent a new approach to clinical design in elderly 
and frail patients. There should also be a more general move to try and discourage 
age being used as a specific exclusion criteria. There should be a greater emphasis 
on treatment outcomes analysis using routine registration of older people with cancer 
into large, comprehensive clinical data sets, though with careful attention to robust 
and standardised measures of co-morbidity, frailty and performance status.  
New methods to measure treatment effects using routine data are also needed. It 
remains to be seen whether initiatives such as the SATURNE project (17), a project 
addressing whether chemotherapy is effective in patients with characteristics out-with 
the eligibility criteria of historical clinical trials, can provide reliable estimation. 
Special considerations for Systemic Anti -Cancer Therapy in older people  
Physiological factors- The biology of certain cancers and their responsiveness to 
therapy changes with a patient’s age. Furthermore, the physiological changes 
associated with aging may impact an older adult’s ability to tolerate cancer therapy.  
Effects of renal function, hepatic metabolism and bone marrow reserve on the 
pharmacokinetic and pharmacodynamic properties of drugs can be considerable.   
Older patients are more likely to have co-morbidities, be malnourished and have 
geriatric syndromes such as incontinence, falls, functional decline, polypharmacy and 
delirium. All of these factors can complicate dosing issues. Furthermore, if patients 
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have other disease states that are the dominant cause of poor quality of life and/or 
reduced life expectancy then treating the cancer may be inappropriate.  
Detection of frailty is particularly important. A systematic review indicated that over 
half of older cancer patients have frailty or pre-frailty, and these patients are at 
considerably increased risk of mortality, post-operative complications and 
chemotherapy intolerance.(18) 
Psychosocial factors - Poor practical and social support can also affect treatment 
tolerance. Older patients who live alone are less likely to accept treatment and 
access to transportation and available networks for home care also influence these 
decisions. (19) (20) 
In patients with dementia there are specific treatment related issues.  In most 
instances, individuals with mild dementia have decision-making capacity if the issues 
are explained to them and they are well supported. In individuals with more 
advanced dementias, carers and families might be asked to make proxy decisions. In 
some cases, the risks outweigh the benefits, for example, in patients with multiple 
comorbidities and high frailty where aggressive treatment might cause more distress. 
However, in individuals with mild dementia and longer life expectancies, the potential 
benefits could be significant and the person should not be denied them based on the 
'dementia' label.  
It should also not be forgotten that elderly patients might have a preference for a 
treatment potentially able to improve their quality of life rather than their survival. In a 
study of preferences for chemotherapy in patients with advanced non-small cell lung 
cancer, few (22%) patients reported they would choose chemotherapy for its likely 
survival benefit of 3 months but substantially more (68%) would choose it if it 
improved their quality of life.(21) 
Optimal use of SACT in older patients requires characterisation of the functional 
reserve of an individual patient, both physically and mentally, along with assessment 
of the extent and severity of co-morbidities and their degree of social support. It 
should, therefore, involve careful decisions about which patients should be offered 
SACT (patient selection), attention to and as far as possible minimisation of SACT 
toxicity and, ideally, optimisation of patients’ health prior to embarking upon SACT. 
Patient Selection   
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Due to the complex interplay between individual genetic and environmental factors 
we all experience ageing differently. Chronological age alone is a poor predictor of 
cancer treatment tolerance and efficacy(22). Work has therefore started to 
investigate risk prediction tools to help assess the individual risk of severe toxicity 
from chemotherapy developed specifically for use in older populations.  
Extermann et al (23) developed the CRASH (Chemotherapy Risk Assessment Scale 
for High-Age Patients) score which stratifies patients aged over 70 years into four 
risk categories (low, medium-low, medium-high, and high) on the basis of both 
chemotherapy and patient variables. The four strongest predictors for haematological 
toxicity were Instrumental Activities of Daily Living score, lactate dehydrogenase 
level, diastolic blood pressure, and toxicity of the chemotherapy regimen. The four 
strongest predictors of non-haematological toxicity were Eastern Cooperative 
Oncology Group (ECOG) performance status (Table 3), Mini-Mental Status score, 
Mini-Nutritional Assessment score, and toxicity of the chemotherapy regimen.  
Hurria et al (24) developed an alternative predictive model identifying patient age, 
(over 72 years) tumour type, receipt of standard dosing chemotherapy or 
polychemotherapy, anaemia & renal dysfunction, and reduced functional status 
(limited ability to walk one block, decreased social activities because of physical or 
emotional problems, falls in the last six months, and the need for assistance with 
taking medications) as risk factors for chemotherapy toxicity. In contrast they found 
that the commonly used Karnofsky Performance Status (KPS) (Table 3) did not 
identify older adults at increased risk for chemotherapy toxicity, highlighting the 
importance of developing risk stratification schema specifically for older adults.  
SACT toxicities   
Measuring Toxicities  
The National Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE) is a descriptive terminology which can be utilized for describing and 
grading adverse events that occur during cancer therapy using drugs, biologics 
radiotherapy or surgery (25). They are also called "common toxicity criteria." Toxicity 
is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-
threatening (Grade 4), with specific parameters according to the organ system 
involved. Death (Grade 5) is used for some of the criteria to denote a fatality. A 
category is a broad classification of Adverse Events based on anatomy and/or 
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pathophysiology. Within each CATEGORY, Adverse Events are listed accompanied 
by their descriptions of severity (Grade). Table 4 shows an example of grading from 
the blood disorders category. 
 
Minimising SACT toxicities 
Chemotherapy toxicities 
Cardiovascular toxicity - Anthracyclines are associated with cardiac toxicity resulting 
in left ventricular dysfunction and congestive heart failure. Risk factors for 
anthracycline induced cardiotoxicity include co-morbidities such as hypertension, 
diabetes and coronary artery disease (all strongly age-related) and older age (a risk 
factor independent of comorbidities and performance status). The International 
Society of Geriatric Oncology (SIOG) have put forward proposals for the 
management of anthracyclines’ cardiotoxicity risk including(26); 
 rigorous screening to exclude patients at unacceptably high cardiac risk  
 reduction in maximum cumulative dose 
 measures to reduce cardiac toxicity (such as use of liposomal formulations, 
prolonged infusions or an iron chelating agent)  
 regular monitoring of cardiac function and early management of dysfunction. 
Nephrotoxicity- the age-related reduction in glomerular filtration rate (GFR) may lead 
to enhanced toxicity of drugs, particularly those with significant renal excretion, such 
as cisplatin, carboplatin, topotecan, methotrexate and ifosfamide. SIOG recommends 
that: 
 renal function should be assessed at least by calculation of creatinine 
clearance in every patient even when serum creatinine is within the normal 
range, and doses adjusted according to degree of renal impairment 
 where possible agents which are less likely to be influenced by renal 
clearance are used  
 co-administration of known nephrotoxic drugs such as NSAIDS or Cox-2 
inhibitors should be avoided or minimized.(27) 
Myelosuppression – Older patients are at higher risk for severe and prolonged 
myelosuppression..(28)(29)(30). Dose reductions and/or interruptions of 
chemotherapy regimens are necessary in patients with severe or life threatening 
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neutropenia, anaemia or thrombocytopenia.  This can impact on outcome as well as 
contribute to a reluctance to administer chemotherapy in older patients, but there is 
some evidence that dose intensification, through dose interval reduction, facilitated 
by prophylactic granulocyte- colony stimulating factor (G-CSF) could improve survival 
in older cancer patients receiving chemotherapy.(31). 
 
Chemotherapy-induced nausea and vomiting (CINV) can significantly affect a 
patient’s quality of life and compliance with treatment. It can also put patients at risk 
of other complications such as acute kidney injury. Anti-emetic therapy with serotonin 
(5-HT3)-receptor antagonists, neurokinin-1-receptor antagonists, and corticosteroids 
can be extremely effective for the management of CINV. However older patients are 
susceptible to increased risk of anti-emetic side effects such as steroid- induced 
diabetes, constipation or QTc prolongation. Selection of appropriate anti-emetic 
therapy should therefore be on an individualised basis (32) (33). 
 
Fatigue - In addition to treating the cancer and prolonging survival, a major goal of 
cancer therapy, especially in the elderly is the preservation of functional 
independence and quality of life. Such functional independence has been shown to 
be compromised by fatigue which has been a major complaint after administration of 
most traditional cytotoxic chemotherapy treatments. (34) (35). Pilot schemes in the 
UK have therefore started trialling the offer of practical or emotional support in the 
form of gardening, cooking, cleaning, transport or befriending to those patients over 
70 embarking on Systemic Anti -Cancer Treatment.(5) 
 
 
Targeted therapy Toxicities  
 
It is widely believed that targeted agents provide effective and less toxic therapy 
while at the same time allowing patients to maintain their functional independence. 
Their use in the elderly patients has therefore been embraced with great hope and 
growing interest. Nonetheless these agents are still associated with some unique and 
potentially severe toxicities which can be more pronounced in the older age group. 
For example; 
Trastuzumab - greater risk of congestive heart failure and left ventricular dysfunction 
Erlotinib - greater rash, stomatitis, dehydration, anorexia and fatigue 
Bevacizumab – greater drug induced hypertension &number of arterial thrombo-
embolic events. 
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Immunotherapy Toxicities 
 
The immunotherapies have the potential to precipitate a wide range of inflammatory 
adverse reactions resulting from increased or excessive immune activity. These 
immune-related reactions may include pneumonitis, heptatitis, colitis, nephrtitis, 
endocrinopathies and rash. They can be life-threatening and appear during the 
treatment course, or after the treatment has completed.  
Awareness of the potential for these toxicities and prompt intervention according to 
specific guidelines (usually available from local oncology services) can prevent the 
toxicities escalating. 
Endocrine Therapy Toxicities 
 
 In patients receiving endocrine therapy physicians need to be vigilant about 
optimising bone, cardiovascular and mental health. Clear guidelines providing 
suggestions of how to best manage these treatment complications such as use of 
appropriate anti-depressants for mood disorders (some are recognised to interact 
with endocrine therapy) and use of appropriate screening and relevant interventions 
to maintain bone and cardiovascular health need to be developed in conjunction with 
relevant specialists and made available to generalists. 
 
Optimising SACT in older patients- a new approach 
Strategies to optimise tolerance of SACT in older patients have hitherto involved 
adapted treatment regimens (dose reduction, selection of particular agents according 
to side effect profile), use of prophylactic G-CSF or rigorous screening to exclude 
patients at unacceptably high risk. More recently there has been a growing 
recognition of the importance of optimizing the physical and psycho- social health of 
older patients prior to receiving SACT. This involves identification of physical and 
psychosocial needs and the International Society of Geriatric Oncology (SIOG) 
recommends the use of Comprehensive Geriatric Assessment (CGA) prior to 
medical or surgical intervention for older cancer patients. This encompasses a review 
of frailty, co –morbidities, geriatric syndromes (eg falls, incontinence), mental health, 
functional difficulties and social circumstances. Rather than using this assessment to 
risk stratify patients, it is being adopted as a clinical process for treatment 
optimisation. 
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Kalsi et al (36) recently carried out a study to evaluate the impact on chemotherapy 
toxicity and tolerance of geriatrician delivered clinical interventions for co-existing 
needs as identified by a CGA for older (>70yrs) patients with cancer. The non-
randomised study involved 135 patients (70 control, 65 intervention) undergoing 
chemotherapy in a London hospital. The observational group received standard 
oncology care. The intervention group underwent risk stratification using a patient 
completed screening questionnaire and high risk patients received CGA. The 
intervention participants undergoing CGA each received a mean of 6  intervention 
plans. These patients were more likely to complete cancer treatment as planned and 
fewer required treatment modifications. Kalsi et al have therefore proposed that 
standard oncology care should shift to a more pro-active model of medically 
optimising elderly patients for SACT, a concept referred to as prehabilitation. (37) 
 
Changing mindsets 
Clearly, to offer aggressive treatment is not always clinically appropriate and 
overtreatment is just as undesirable as undertreatment. However advanced age 
alone should not be an exclusion criteria for the use of effective cancer treatment that 
could improve quality of life or extend meaningful survival and it is evident that there 
is much work to be done to ensure that we are not failing older patients. The recent 
UK Department of Health’s ‘Cancer services Coming of Age report’ (5) has set out 
key principles for the development of an ‘ age friendly cancer service.’ (Box1). 
The Independent Cancer Taskforce has also specifically recognised the needs of 
older people in their recently published National Cancer Strategy, proposing 
recommendations outlined below (Box 2) (38). 
Conclusion 
With an ageing population, a rapid expansion of the range of systemic anti-cancer 
therapy options available and the increasing chronic nature of cancer management, it 
is inevitable that that there will be an expanding number of elderly patients living with, 
and undergoing treatment for, cancer. These patients will require medical 
professionals who are equipped to help them decide the best treatment course for 
their cancer, to ensure that they are in the optimum condition to receive it and to help 
them manage potential ongoing complications of their disease or its treatment. In 
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order to do this we need to improve the evidence base for the use of systemic anti-
cancer treatments in older patients by increasing recruitment of older patients to 
clinical trials. We also need to work on improving links between elderly care 
specialists and oncologists to ensure we provide a cancer service that is tailored to 
meet the specific, and often complex, physiological and psycho–social needs of this 
growing cohort of patients.  
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Appendix 
 
Table 2  
Examples of adverse effects associated with targeted anti-cancer therapy and 
immunotherapy  
 immunotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapy Target Tumour 
type used 
to treat 
Potential adverse side effects 
Bevacizumab Vascular endothelial  
growth factor (VEGF) 
Colorectal, 
ovarian  
Gastrointestinal perforation, wound healing 
complications, haemorrhage, arterial and venous 
thrombo-embolism, proteinuria, hypertension, 
reversible posterior leucoencephalopathy syndrome 
(RLPS) 
Trastuzumab Human epidermal 
growth factor 
receptor 2 (HER2) 
Breast Cardiomyopathy, especially if co-administered with 
anthracyline chemotherapy, infusion related reaction 
Erlotinib Epidermal growth 
factor receptor 
(EGFR) tyrosine 
kinase 
Lung Acneiform rash, diarrhoea, nausea and vomiting, 
elevated liver enzymes, pneumonitis 
Sunitinib Multiple receptor 
tyrosine kinases 
Renal Fatigue, skin discolouration, haemorrhage, 
stomatitis, nausea&vomiting, hypertension, 
hypothyroidism, osteonecrosis of the jaw 
Ipilimumab Cytotoxic T-
lymphocyte 
associated antigen 4 
(CTLA-4) 
Melanoma Fatigue, rash, colitis, hepatitis, hypophysitis, 
hypo/hyperthyroidism, hypopituitarism 
Pembrolizumab Programmed cell 
death 1 (PD-1) 
immune checkpoint 
inhibitor 
Melanoma
, lung 
Fatigue, rash, colitis, hepatitis, 
hypo/hyperthyroidism, arthralgia, myalgia, 
pneumonitis 
 
 
 
 
 
 
 
 
Table1 
Examples of adverse effects associated with traditional chemotherapeutic 
agents  
 
 
  Chemotherapy Class Example Tumour type used 
to treat 
Potential Adverse Side Effects in 
addition to fatigue, myelosuppression, 
nausea & vomiting 
Alkylating agents Cisplatin, 
carboplatin, 
cyclophosphamide 
Lung,ovarian , 
testicular,breast 
Nephrotoxicity, ototoxicity, 
thromboembolic events 
Anthracyclines Epirubicin, 
doxorubicin 
Breast, sarcoma Alopecia, cardiotoxicity, secondary 
malignanices 
Taxanes Paclitaxel, 
docetaxel 
Ovarian, breast , 
lung 
Alopecia, peripheral neuropathy, 
arthralgia, hypersensitivity reaction, 
diarrhoea 
Vinca alkaloids Vincristine, 
vinorelbine 
Breast, lung Headache, constipation, peripheral 
neuropathy 
Anti- metabolites Methotrexate, 5 – 
fluorouracil, 
capecitabine, 
gemcitabine 
Colorectal, 
oesophageal, lung 
Hand- foot syndrome, cardiotoxicity, 
nephrotoxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3  
Table comparing the Eastern Cooperative Oncology Group (ECOG) Performance 
Status to the Karnofsky Performance Status (KPS)  
   
ECOG PERFORMANCE STATUS KARNOFSKY PERFORMANCE STATUS 
0—Fully active, able to carry on all pre-
disease performance without restriction 
100—Normal, no complaints; no evidence of 
disease 
90—Able to carry on normal activity; minor signs or 
symptoms of disease 
1—Restricted in physically strenuous 
activity but ambulatory and able to carry 
out work of a light or sedentary nature, 
e.g., light house work, office work 
80—Normal activity with effort, some signs or 
symptoms of disease 
70—Cares for self but unable to carry on normal 
activity or to do active work 
2—Ambulatory and capable of all 
selfcare but unable to carry out any work 
activities; up and about more than 50% of 
waking hours 
60—Requires occasional assistance but is able to 
care for most of personal needs 
50—Requires considerable assistance and frequent 
medical care 
3—Capable of only limited selfcare; 
confined to bed or chair more than 50% 
of waking hours 
40—Disabled; requires special care and assistance 
30—Severely disabled; hospitalization is indicated 
although death not imminent 
4—Completely disabled; cannot carry on 
any selfcare; totally confined to bed or 
chair 
20—Very ill; hospitalization and active supportive 
care necessary 
10—Moribund 
5—Dead 0—Dead 
 
Table 4 
Adapted from National Cancer Institute Common Terminology Criteria for  
Haematological Toxicity 
 
Blood 
element 
 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Grade 3 
( severe) 
Grade 4 
( life-
threatening) 
Grade 5 
Neutrophils <reference 
range to 1.5 
x 109/L 
 
1 to 1.5 x 
109/L 
0.5 to 1 x 
109/L 
<0.5 x 109/L  
Platelets <reference 
range to 75 
x109/L 
 
50 to75 x 
109/L 
25 to 50 x 
109/L 
<25 x 109/L  
Haemoglobin <reference 
range to 
100g/L 
80 to 100g/L <80g/L Life- 
threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
                
Box 1 - Key principles for the development of an age friendly cancer service from 
CANCER SERVICES COMING OF AGE , a report from the Department of Health. 
 
• Engaging elderly care specialists as an active part of the cancer care team. 
• Adoption of a multidisciplinary approach to the assessment and management of all 
patients. 
• Ensuring an early and appropriate assessment of an older person to identify and 
address unmet physical, psychological and social support needs prior to embarking on 
cancer treatment with further follow up assessments to be undertaken at defined points 
throughout the treatment journey, to identify and address changes in need.    
• Effective management of other health conditions and incorporating reasonable 
adjustments into care planning to address additional needs.    
• Establishment of services and clear referral pathways to address needs identified by 
assessment. This includes establishing clear links with voluntary sector agencies, social 
services, and specialist teams such as falls prevention teams, continence specialists 
and dementia specialists. 
 
Box 2- Recommendations for achieving world class cancer outcomes in older people 
from ACHIEVING WORLD-CLASS CANCER OUTCOMES A STRATEGY FOR ENGLAND 
2015-2020, a report from the independent Cancer Taskforce. 
• Recommendation 41: NHS England, the Trust Development Authority and Monitor 
should pilot a comprehensive care pathway for older patients (aged 75 and over in the 
first instance). This pathway should incorporate an initial electronic health needs 
assessment, followed by a frailty assessment, and then a more comprehensive geriatric 
needs assessment if appropriate. The pilot should evaluate a model in which the 
outputs of these assessments are considered by the MDT in the presence of a 
geriatrician, who would advise on Allied Health Professional needs, co-morbidities etc, 
and their implications for treatment and emotional and physical support.  
• Recommendation 42: NHS England should ask the National Institute for Health 
Research and research charities to develop research protocols which enable a better 
understanding of how outcomes for older people could be improved. 
  
